-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
On April 19, CSPC announced that its subsidiary CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.
According to the announcement, Duensibu capsules are declared in accordance with the 5.
According to public information, it is speculated that the new drug is Copiktra (duvelisib) introduced by CSPC from Verastem Oncology in September 2018.
Duvelisib's approval in the United States for the treatment of FL is mainly based on a single-arm, multi-center phase 2 clinical trial.
Follicular lymphoma is a common type of lymphoma and the most common type of indolent lymphoma.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
Reference materials:
[1]Voluntary Announcement-The National Medical Products Administration accepts the listing application of "Duensibu Capsules".